Product Code: ETC6186370 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The non-alcoholic steatohepatitis (NASH) market in Australia is growing due to increasing cases of obesity and metabolic syndrome. Pharmaceutical treatments and lifestyle interventions are driving the market as awareness about liver health increases.
The non-alcoholic steatohepatitis market in Australia is driven by increasing cases of obesity, type 2 diabetes, and metabolic syndrome. Rising investment in drug development, increasing availability of diagnostic tools, and growing awareness about liver health are fueling market growth. Government support for clinical trials and increasing demand for combination therapies are also supporting market expansion.
The non-alcoholic steatohepatitis (NASH) market in Australia faces challenges from high drug development and clinical trial costs. Regulatory requirements for drug safety and efficacy increase market entry barriers. Limited awareness among healthcare providers and patients reduces market demand. High treatment costs and limited government reimbursement further restrict market expansion.
The non-alcoholic steatohepatitis (NASH) market in Australia is expanding due to increasing obesity and diabetes rates. NASH is a severe form of fatty liver disease with limited treatment options. Investment opportunities lie in developing new drug therapies, improving diagnostic capabilities, and expanding patient access to specialized healthcare services. Growth in liver health awareness and government support for metabolic disease research are driving market growth.
Non-alcoholic steatohepatitis (NASH) treatments, including drugs and lifestyle programs, are regulated by the TGA. The PBS covers certain medications used to manage NASH. The government funds research into liver diseases through the MRFF. Public health campaigns focus on raising awareness about obesity and metabolic syndrome, which are key drivers of NASH. Import and export of NASH medications are controlled under pharmaceutical trade laws.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Non-alcoholic Steatohepatitis Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Non-alcoholic Steatohepatitis Market - Industry Life Cycle |
3.4 Australia Non-alcoholic Steatohepatitis Market - Porter's Five Forces |
3.5 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Sales Channel, 2021 & 2031F |
3.7 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By Disease Cause, 2021 & 2031F |
3.8 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Australia Non-alcoholic Steatohepatitis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Non-alcoholic Steatohepatitis Market Trends |
6 Australia Non-alcoholic Steatohepatitis Market, By Types |
6.1 Australia Non-alcoholic Steatohepatitis Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Vitamin E and Pioglitazone, 2021- 2031F |
6.1.4 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Ocaliva, 2021- 2031F |
6.1.5 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Elafibranor, 2021- 2031F |
6.1.6 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Selonsertib and Cenicriviroc, 2021- 2031F |
6.1.7 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Obeticholic Acid, 2021- 2031F |
6.1.8 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Australia Non-alcoholic Steatohepatitis Market, By Sales Channel |
6.2.1 Overview and Analysis |
6.2.2 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.2.3 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Online Providers, 2021- 2031F |
6.2.4 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.3 Australia Non-alcoholic Steatohepatitis Market, By Disease Cause |
6.3.1 Overview and Analysis |
6.3.2 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hypertension, 2021- 2031F |
6.3.3 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Heart Disease, 2021- 2031F |
6.3.4 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By High Blood Lipid, 2021- 2031F |
6.3.5 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Type 2 Diabetes, 2021- 2031F |
6.3.6 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Obesity, 2021- 2031F |
6.4 Australia Non-alcoholic Steatohepatitis Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Australia Non-alcoholic Steatohepatitis Market Revenues & Volume, By Homecare settings, 2021- 2031F |
7 Australia Non-alcoholic Steatohepatitis Market Import-Export Trade Statistics |
7.1 Australia Non-alcoholic Steatohepatitis Market Export to Major Countries |
7.2 Australia Non-alcoholic Steatohepatitis Market Imports from Major Countries |
8 Australia Non-alcoholic Steatohepatitis Market Key Performance Indicators |
9 Australia Non-alcoholic Steatohepatitis Market - Opportunity Assessment |
9.1 Australia Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Australia Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Sales Channel, 2021 & 2031F |
9.3 Australia Non-alcoholic Steatohepatitis Market Opportunity Assessment, By Disease Cause, 2021 & 2031F |
9.4 Australia Non-alcoholic Steatohepatitis Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Australia Non-alcoholic Steatohepatitis Market - Competitive Landscape |
10.1 Australia Non-alcoholic Steatohepatitis Market Revenue Share, By Companies, 2024 |
10.2 Australia Non-alcoholic Steatohepatitis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |